BioSpace News Archive

Vivos Therapeutics, Inc today announced it has entered into an exclusive distribution agreement with GM Instruments, Ltd. for the distribution of GM Instruments’ NR6 Rhinomanometer.

HTG Molecular Diagnostics, Inc. announced the customer publication of a peer reviewed journal article featuring the HTG Transcriptome Panel less than one year after the breakthrough product’s commercial release.

Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor.

Humacyte, Inc. today announced that an analysis of the potential of the Human Acellular Vessel (HAV) to expand vascular surgical treatment options has been published online in the Journal of the American Medical Association (JAMA) companion journal Surgery.

Codiak BioSciences, Inc. today announced the initiation of patient dosing in its Phase 1 clinical trial of exoASO-STAT6.

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: FASEB’s The Genome Engineering Conference: Cutting-Edge Research and Applications on June 29, 2022 at 5:30 p.m. WET/12:30 p.m. ET in Lisbon, Portugal.

The global leader in the fight against blood cancers, The Leukemia & Lymphoma Society (LLS), announced the launch of its Pediatric Acute Leukemia (PedAL) Master Clinical Trial, an unprecedented international collaboration led by LLS designed to fundamentally change how children with acute leukemias are treated.

Invictus Sterilization LLC., a Hickory, NC based provider of Hospital-Grade UV-C based surface and air sterilization products, announced today that the U.S. Food and Drug Administration (FDA) cleared its Aura Storm as a Class II ultraviolet medical air purifier.